share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  07/02 08:04
Moomoo AI 已提取核心信息
On July 2, 2024, 180 Life Sciences Corp. announced that it has received an extension from the Nasdaq Hearings Panel to meet the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. The company must file a public disclosure by July 31, 2024, detailing the transactions undertaken to achieve compliance with Nasdaq's listing rules and demonstrate long-term compliance with the Equity Rule. Previously, 180 Life Sciences was notified of non-compliance with the Equity Rule, which requires a minimum stockholders' equity of $2.5 million. The company had been granted an extension until May 13, 2024, to regain compliance but failed to do so, leading to a delisting determination. The company appealed, and the delisting action was stayed pending the Hearings Panel's decision. Despite the extension, there is no assurance that 180 Life Sciences will meet the conditions or regain compliance with the listing requirements.
On July 2, 2024, 180 Life Sciences Corp. announced that it has received an extension from the Nasdaq Hearings Panel to meet the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. The company must file a public disclosure by July 31, 2024, detailing the transactions undertaken to achieve compliance with Nasdaq's listing rules and demonstrate long-term compliance with the Equity Rule. Previously, 180 Life Sciences was notified of non-compliance with the Equity Rule, which requires a minimum stockholders' equity of $2.5 million. The company had been granted an extension until May 13, 2024, to regain compliance but failed to do so, leading to a delisting determination. The company appealed, and the delisting action was stayed pending the Hearings Panel's decision. Despite the extension, there is no assurance that 180 Life Sciences will meet the conditions or regain compliance with the listing requirements.
2024年7月2日，180 life sciences公司宣布获得纳斯达克听证会小组的延期，以达到纳斯达克资本市场的最低股东权益要求。公司必须在2024年7月31日之前公开披露交易细节，以便符合纳斯达克的上市规则并证明长期符合资产准则。此前，180 life sciences曾被告知不符合资产准则，该准则要求最低股东权益为250万美元。该公司曾获得延期至2024年5月13日，以重新达到合规交易，但未能做到，导致被摘牌。该公司已进行上诉，摘牌行动已被暂缓，直至听证会小组作出决定。尽管延期，但无法保证180 life sciences将符合条件或恢复符合上市要求。
2024年7月2日，180 life sciences公司宣布获得纳斯达克听证会小组的延期，以达到纳斯达克资本市场的最低股东权益要求。公司必须在2024年7月31日之前公开披露交易细节，以便符合纳斯达克的上市规则并证明长期符合资产准则。此前，180 life sciences曾被告知不符合资产准则，该准则要求最低股东权益为250万美元。该公司曾获得延期至2024年5月13日，以重新达到合规交易，但未能做到，导致被摘牌。该公司已进行上诉，摘牌行动已被暂缓，直至听证会小组作出决定。尽管延期，但无法保证180 life sciences将符合条件或恢复符合上市要求。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息